Clinical analysis and risk management of drug-induced hyperuricemia

Published on Sep. 28, 2023Total Views: 1869 times Total Downloads: 457 times Download Mobile

Author: Xiao-Lei REN ¹ Yi-Qiu ZHAN ¹ Chun-Yan ZHANG ¹  Lin HUANG ¹  Yu-Fei FENG ²

Affiliation: 1. Department of Pharmacy, Peking University People's Hospital, Beijing 100044, China 2. Clinical Trial Site, Peking University People's Hospital, Beijing 100044, China

Keywords: Hyperuricemia Drug-induced Drug safety Risk management

DOI: 10.19960/j.issn.1005-0698.202309002

Reference: Xiao-Lei REN, Yi-Qiu ZHAN, Chun-Yan ZHANG, Lin HUANG, Yu-Fei FENG.Clinical analysis and risk management of drug-induced hyperuricemia[J].Yaowu Liuxingbingxue Zazhi,2023, 32(9):969-974.DOI: 10.19960/j.issn.1005-0698.202309002.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Objective To discuss the occurrence characteristics of drug-induced hyperuricemia based on clinical examples, and to provide evidence for clinical drug safety and risk management.

Methods Case reports of drug-induced hyperuricemia publicly published in medical journals from inception to December 31, 2022 were retrieved, and adverse drug reaction (ADR) reports of drug-induced hyperuricemia reported in our hospital from 2010 to 2022 were collected. The information such as patient gender, age, suspected drugs, drug usage and dosage, blood uric acid level, ADR induction time, treatment and prognosis for statistical analysis was extracted.

Results There were 18 cases searched for literature, and our hospital reported 27 cases of hyperuricemia related to ADR, totaling 45 cases, including 25 males and 20 females, aged 14-82 years, with an average age of (53.18±19.45) years. Drug-induced hyperuricemia mainly involved antituberculosis drugs, diuretics, antiinfective drugs, compound antihypertensive drugs, antiplatelet drugs, proton pump inhibitors, immunomodulatory drugs and antipsychotics. Among the 45 patients after treatment, serum uric acid was >420-480 μmol·L^-1 in 4 cases, >480-540 μmol·L^-1 in 13 cases, and >540 μmol·L^-1 in 28 cases. The time it takes to induce hyperuricemia varies from 2 days to several years. After drug withdrawal, symptomatic treatment or dose reduction, blood uric acid level decreased or returned to normal.

Conclusions A variety of drugs can cause hyperuricemia. Patients taking these drugs, especially elderly patients, should monitor the blood uric acid levels regularly. Medical staff should know the drugs causing hyperuricemia, and do a good job in medication risk management to reduce the occurrence of drug-induced hyperuricemia.

Full-text

Please download the PDF version to read the full text: download

References

1.范茂丹, 徐芬, 杨敏.27例药源性高尿酸血症的药物使用分析及处理措施[J]. 中国疗养医学, 2012, 21(2): 168. [Fan MD, Xu F, Yang M. Analysis and treatment of drug use in 27 cases of drug-induced hyperuricemia[J]. Chinese Journal of Convalescent Medicine, 2012, 21(2): 168.] DOI: 10.13517/j.cnki.ccm.2012.02.037.

2.中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019) [J].中华内分泌代谢杂志, 2020, 36(1): 1-13. DOI: 10.3760/cma.j.issn.1000-6699.2020.01.001.

3.秦贵军. 药源性高尿酸血症[J]. 药品评价, 2015, 12(7): 19-22. [Qin GJ. Drug-induced hyperuricemia[J]. Drug evaluation, 2015, 12(7): 19-22.] DOI: 10.3969/j.issn. 1672-2809.2015.07.006.

4.国家药品不良反应监测中心. 药品不良反应报告和监测工作手册[EB/OL]. (2012-11-01) [2019-06-29].http://111.202.232.186 /CDR/help /index /index.html.

5.中华医学会内分泌学分会. 高尿酸血症和痛风治疗的中国专家共识[J]. 中华内分泌代谢杂志, 2013, 29(11): 913-918. DOI: 10.3760/cma.j.issn.1000-6699. 2013.11.001.

6.中国老年保健医学研究会老年内分泌与代谢病分会. 老年人多重用药安全管理专家共识[J]. 中国糖尿病志, 2018, 26(9): 705-717. DOI: 10.3969/j.issn.1006-6187. 2018.09.001.

7.蒲强红, 李佳萌, 李凡敏, 等.结核病化疗药物吡嗪酰胺致高尿酸血症的危险因素研究[J].中华全科医学, 2021, 19(12): 2058-2060. [Pu QH, Li JM, Li FM, et al. Risk factors for tuberculosis chemotherapeutic drug pyrazinamide-induced hyperuricemia[J]. Chinese Journal of General Practice, 2021, 19(12): 2058-2060.] DOI: 10.16766/j.cnki.issn.1674-4152.002236.

8.Bruderer S, Bodmer M, Jick SS, et al. Use of diuretics and risk of incident gout: a population-based case-control study[J]. Arthritis Rheumatol, 2014, (66): 185. DOI: 10.1002/art.38203.

9.张海英, 卓来东, 李玉珍. 小剂量阿司匹林对正常小鼠及高尿酸血症模型小鼠血尿酸的影响[J]. 中国新药杂志, 2009, 18(5): 434-436. [Zhang HY, Zhuo LD, Li YZ. Effect of mini-dose aspirin on uric acid in normal and hyperuricemic mice[J]. Chinese Journal of New Drugs, 2009, 18(5): 434-436.] DOI: 10.3321/j.issn:1003-3734. 2009.05.018.

10.Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects[J]. Drug Metab Dispos, 2010, 38(9): 1514-1521. DOI: 10.1124/dmd.110.032250.

11.Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism[J]. J Thromb Haemost, 2013, 11(10): 1867-1876. DOI: 10.1111/jth.12360.

12.袁钢, 许晴晴, 吴旭. 探讨质子泵抑制剂(PPIs)对痛风活动的影响机制[J]. 内蒙古中医药, 2013, 32(9): 50-51. [Yuan G, Xu QQ, Wu X. To investigate the mechanism of proton pump inhibitors (PPIs) on gout activity[J]. Inner Mongolia Journal of Traditional Chinese Medicine, 2013, 32(9): 50-51.] DOI: 10.3969/j.issn.1006-0979. 2013.09.051.

13.周捷.药源性高尿酸血症的致病药物及防治对策[J].中国现代药物应用, 2008, 2(16): 108-109. [Zhou J. Drug-induced hyperuricemia about its causative drugs and preventive and therapeutic methods[J]. Chinese Journal of Modern Drug Application, 2008, 2(16): 108-109.] DOI: 10.3969/j.issn.1673-9523.2008.16.110.

14.田娜妮, 何青青, 朱琳, 等.吡嗪酰胺相关高尿酸血症的影响因素分析[J]. 中国医药导刊, 2022, 22(4): 389-392. [Tian NN, He QQ, Zhu L, et al. Analysis of influencing factors of hyperuricemia induced by pyrazinamide[J]. Chinese Journal of Medicinal Guide, 2022, 22(4): 389-392.] DOI: 10.3969/j.issn.1009-0959.2022.04.016.

15.中国医疗保健国际交流促进会高血压分会共识专家组. 高血压伴无症状高尿酸血症管理中国专家共识[J].

中华高血压杂志, 2022, 30(11): 1014-1019. DOI: 10.16 439/j.issn.1673-7245.2022.11.004.

16.赵雅茜, 陈桃, 孙蕊, 等. 无症状高尿酸血症的诊治争议[J]. 中国临床新医学, 2021, 14(11): 1068-1071. [Zhao YX, Chen T, Sun R, et al. The debate on diagnosis and treatment of asymptomatic hyperuricemia[J]. Chinese Journal of New Clinical Medicine, 2021, 14(11): 1068-1071.] DOI: 10.3969/j.issn.1674-3806.2021.11.02.